Real-world outcomes associated with the use of the EmboTrap revascularization device for ischemic stroke in the United States

• Published in: Journal of neurointerventional surgery Vol. 14; no. 11; pp. 1068 - 1072
• Main Authors: Brinjikji, Waleed, Ikeme, Shelly, Kottenmeier, Emilie, Khaled, Alia, M, Sidharth, Khanna, Rahul
• Format: Journal Article
• Language: English
• Published: BMA House, Tavistock Square, London, WC1H 9JR BMJ Publishing Group Ltd 01.11.2022; BMJ Publishing Group LTD
• Subjects: Age groups; Cardiac arrhythmia; Cardiovascular disease; Coronary vessels; Diabetes; Health facilities; Heart failure; Hospital costs; Hypertension; Ischemic stroke; Medicaid; Medical equipment; Medicare; Metabolic disorders; Mortality; Pandemics; Patients; Stroke; thrombectomy; Vein & artery diseases; United States > US
• ISSN: 1759-8478; 1759-8486
• DOI: 10.1136/neurintsurg-2021-018175

BackgroundMechanical thrombectomy (MT) has become the standard of care for the treatment of acute ischemic stroke (AIS). The EmboTrap revascularization device (CERENOVUS, Johnson & Johnson Medical Devices, Irvine, California, USA) has an innovative, dual layer feature designed to facilitate thrombus retrieval.ObjectiveTo investigate the real-world clinical and economic outcomes among patients with AIS undergoing MT using the EmboTrap device in the United States (US).MethodsAdult patients (≥18 years) who underwent MT for AIS using the EmboTrap device between July 2018 and December 2020 were identified from the Premier Healthcare Database. Patient outcomes included discharge status (including in-hospital mortality), mean length of stay (LOS), intracranial hemorrhage (ICH), mean hospital costs, and 30-day readmissions (all-cause, cardiovascular (CV)-related, and AIS-related).ResultsA total of 318 patients (mean age 68.5±14.6 years) with AIS treated with the EmboTrap device as the only stent retriever used were identified. Approximately 25% of patients were discharged to home/home health organization, and the in-hospital mortality rate was 10.7%. The rate of ICH was 16.7%. Mean hospital LOS was 9.9±11.3 days, and the mean hospital costs were US$47 367±30 297. The 30-day readmission rate was 9.6% for all-causes, 5.9% for CV-related causes, and 2.6% for AIS-related causes.ConclusionsThis is the first study in the US to report real-world outcomes sourced by retrospective database analysis among patients with AIS undergoing MT using the EmboTrap device. Further research is needed to better understand performance of the EmboTrap device in real-world settings.